Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have ...
Hosted on MSN1h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug WarsShares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds ...
The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...
Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...
A Super Bowl ad touting Hims & Hers Health Inc.’s copycat weight-loss drugs is getting pushback from the branded drugmakers’ ...
The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback